About the Problem Statement:

Teijin Pharma Limited (Teijin) is looking for solutions to treat neurological diseases in the Japanese population.

Hardware MedTech startups for neuromodulation and software startups experience in healthcare for a mobile app would be relevant.

Objectives:

To save and reduce patients with neurological diseases relating to the central nervous system, including psychiatric and neurodegenerative diseases. Solution examples include user-friendly therapeutic modalities like non-invasive neuromodulation and/or digital therapeutics at home.

Working Model:

Teijin is open to discussing the collaboration model with startups but typically takes responsibility for technology development for the Japanese market, conducting clinical studies, regulatory / reimbursement tasks and finally commercialisation in Japan.

To achieve the goal, Teijin will invest with dilutive (equity) and/or non-dilutive funding in the partner(s).

About the Problem Statement:

Teijin Pharma Limited (Teijin) is looking for solutions for the ageing population to correctly understand their own health conditions.

Startups with capabilities to develop AI algorithms based on health / vital data for chronic diseases and startups with technologies for sensing vital signals for chronic diseases would be relevant.

Objectives:

To provide an easy solution for the ageing population with chronic diseases to proactively understand their own health conditions from the patients’ homes. This includes, but should not be limited to, innovative technology to predict exacerbation before their illness gets worse.

Working Model:

Teijin is open to discussing the collaboration model with startups but typically takes responsibility for technology development for the Japanese market, conducting clinical studies, regulatory / reimbursement tasks and finally commercialisation in Japan.

To achieve the goal, Teijin will invest with dilutive (equity) and/or non-dilutive funding in the partner(s).

About the Problem Statement:

The diagnosis of non-radiographic axial spondyloarthritis (nr-AxSpA) is complicated and at times protracted, beginning with a clinician’s interpretation of X-rays and requiring an MRI (Magnetic Resonance Imaging) for confirmation.

About the Problem Statement:

One of the future growth pillars for Mitsubishi Chemical Holdings Corporation’s (MCHC) healthcare business is to provide ‘around the pill solutions’ enabled by digital technology, intended to improve the quality of life of patients and their families, in their core therapeutics areas. Therapeutics areas of interest include the central nervous system (especially neuromuscular disease), autoimmune diseases and metabolic diseases.

Objectives:

To establish multiple touchpoints with patients during the patient journey from prevention to prognosis, to collect and analyse healthcare data and expand the value of current treatments.

Examples of such solutions could be digital platforms enabling patient-centric disease management, electronic patient-reported outcomes, digital diagnostics, disease tracking, digital medication management, digital biomarker, etc.